
Akers Biosciences, Inc. AKER
Akers Biosciences, Inc. Income Statement 2011-2026 | AKER
Annual Income Statement Akers Biosciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
809 K | 888 K | 6.36 M | 1.2 M | 3.26 M | 3.08 M | 8 M | 4.14 M | - | - |
Shares |
306 K | 306 K | 229 K | 24.7 K | 14.1 K | 13.4 K | 12.4 K | 4.16 K | - | - |
Net Income |
-17.6 M | -3.89 M | -10.8 M | -5.81 M | -3.3 M | -9.31 M | -3.13 M | -1.53 M | -2.45 M | -3.58 M |
Revenue |
- | 1.58 M | 1.67 M | 3.93 M | 2.96 M | 2.12 M | 4.43 M | 3.58 M | 1.52 M | 1.79 M |
EBITDA |
-12.3 M | -3.76 M | -8.38 M | -4.88 M | -4.46 M | -6.82 M | -2.95 M | -1.55 M | -2.19 M | -3.33 M |
Operating Expenses |
7.99 M | 4.28 M | 8.68 M | 7.56 M | 6.51 M | 8.22 M | 6.46 M | 3.47 M | 3.17 M | 4.74 M |
General and Administrative Expenses |
- | 3.73 M | 5.67 M | 4.08 M | 3.01 M | 4.03 M | 3.98 M | 1.52 M | 1.49 M | 3.28 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Akers Biosciences, Inc. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Baxter International
BAX
|
$ 21.07 | 1.81 % | $ 10.7 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 202.8 | -1.16 % | $ 58.3 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
ICU Medical
ICUI
|
$ 151.86 | 0.14 % | $ 3.7 B | ||
|
iRhythm Technologies
IRTC
|
$ 180.4 | -4.68 % | $ 5.63 B | ||
|
Repro Med Systems
KRMD
|
$ 5.67 | -2.41 % | $ 259 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Masimo Corporation
MASI
|
$ 140.04 | 1.54 % | $ 7.46 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Merit Medical Systems
MMSI
|
$ 86.37 | -7.31 % | $ 5.03 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 8.03 | -1.95 % | $ 162 M | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Alcon
ALC
|
$ 80.27 | -0.43 % | $ 40.4 B | ||
|
Predictive Oncology
POAI
|
$ 6.83 | 1.08 % | $ 37.2 M | ||
|
AtriCure
ATRC
|
$ 41.66 | -1.76 % | $ 1.96 B | ||
|
electroCore
ECOR
|
$ 5.62 | 11.73 % | $ 31 K | ||
|
Haemonetics Corporation
HAE
|
$ 82.2 | -2.19 % | $ 4.14 B | ||
|
AngioDynamics
ANGO
|
$ 9.97 | -0.8 % | $ 407 M | ||
|
Harvard Bioscience
HBIO
|
$ 0.64 | -1.79 % | $ 27.1 M | ||
|
The Cooper Companies
COO
|
$ 83.71 | 0.69 % | $ 16.7 B | ||
|
LeMaitre Vascular
LMAT
|
$ 84.83 | -0.25 % | $ 1.9 B | ||
|
Glaukos Corporation
GKOS
|
$ 113.09 | -0.93 % | $ 5.48 B | ||
|
InfuSystem Holdings
INFU
|
$ 8.61 | -4.01 % | $ 178 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Nephros
NEPH
|
$ 4.89 | -2.5 % | $ 50.8 M | ||
|
Utah Medical Products
UTMD
|
$ 59.83 | 1.87 % | $ 217 M | ||
|
Intuitive Surgical
ISRG
|
$ 587.18 | 0.36 % | $ 209 B | ||
|
Microbot Medical
MBOT
|
$ 2.08 | -5.02 % | $ 21.2 M | ||
|
Milestone Scientific
MLSS
|
$ 0.3 | 1.23 % | $ 23.9 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
$ 23.57 | -0.23 % | $ 4.06 B | ||
|
OraSure Technologies
OSUR
|
$ 2.63 | -1.13 % | $ 196 M | ||
|
Pro-Dex
PDEX
|
$ 41.51 | 0.51 % | $ 136 M | ||
|
Pulse Biosciences
PLSE
|
$ 14.63 | -0.61 % | $ 703 M | ||
|
Repligen Corporation
RGEN
|
$ 166.85 | 0.26 % | $ 9.3 M | ||
|
ResMed
RMD
|
$ 252.15 | 0.49 % | $ 36.8 B | ||
|
BioLife Solutions
BLFS
|
$ 24.8 | -0.6 % | $ 1.14 B | ||
|
STERIS plc
STE
|
$ 258.0 | -1.03 % | $ 25.4 B | ||
|
Stereotaxis
STXS
|
$ 2.53 | -2.13 % | $ 204 M | ||
|
Retractable Technologies
RVP
|
$ 0.76 | -2.53 % | $ 22.8 M | ||
|
STAAR Surgical Company
STAA
|
$ 22.06 | -1.96 % | $ 1.08 B | ||
|
Teleflex Incorporated
TFX
|
$ 112.75 | 2.49 % | $ 5.28 B | ||
|
West Pharmaceutical Services
WST
|
$ 275.51 | 0.1 % | $ 20.1 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 12.76 | 2.2 % | $ 2.59 B |